SCHEMBL1551772

SCHEMBL1551772

CCC(C)OOC(=O)OOC(C)CC

nearest known ligand 0.36

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.32
ACACB O00763 1/20 0.31
SOAT1 P35610 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL542303 0.91
SCHEMBL2208988 0.88 MAPT (0.33) TSHR
SCHEMBL27465424 0.86 TSHR (0.37) TSHR
SCHEMBL2208992 0.85 ALDH1A1 (0.31) ALDH1A1
SCHEMBL5853580 0.83
SCHEMBL446240 0.82
SCHEMBL6824214 0.80 MAPT (0.31) ALDH1A1
SCHEMBL356089 0.80 ALDH1A1 (0.33) ALDH1A1
SCHEMBL28632969 0.80 MAPT (0.31) ALDH1A1
SCHEMBL5517805 0.80 TSHR (0.36) ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12434265-B2 Coating method TOKUYAMA CORPORATION (JP) 2025-10-07 US disclosed
EP-3480651-B1 SPECTACLE LENS AND SPECTACLES HOYA LENS THAILAND LTD (TH) 2023-09-13 EP disclosed
US-20220234072-A1 COATING METHOD TOKUYAMA CORPORATION (JP) 2022-07-28 US disclosed
CN-111757910-B Sealing resin composition 味之素株式会社 2022-06-24 CN disclosed
EP-4000750-A1 COATING METHOD Tokuyama Corporation (JP) 2022-05-25 EP disclosed
US-10913226-B2 Method for manufacturing spectacle lens HOYA LENS THAILAND LTD. (TH) 2021-02-09 US disclosed
WO-2021015138-A1 COATING METHOD 株式会社トクヤマ 2021-01-28 WO disclosed
EP-3480635-A1 METHOD FOR MANUFACTURING SPECTACLE LENS Hoya Lens Thailand Ltd. (TH) 2019-05-08 EP disclosed
EP-3480651-A1 SPECTACLE LENS AND SPECTACLES Hoya Lens Thailand Ltd. (TH) 2019-05-08 EP disclosed
EP-1602479-B1 LAYERED PRODUCT, OPTICAL PART, PROCESSES FOR PRODUCING THESE, AND COATING FLUID TOKUYAMA CORP (JP) 2019-04-10 EP disclosed
US-20040014995-A1 Chromene compounds KAWABATA YUICHIRO (JP) 2004-01-22 US disclosed
US-20030096117-A1 Chromene compound TOKUYAMA CORPORATION (JP) 2003-05-22 US disclosed
EP-1293522-A1 CURABLE COMPOSITION COMPRISING PHOTOCHROMIC COMPOUND TOKUYAMA CORPORATION (JP) 2003-03-19 EP disclosed
EP-1291388-A1 CURABLE COMPOSITION AND PHOTOCHROMIC CURED ARTICLE TOKUYAMA CORPORATION (JP) 2003-03-12 EP disclosed
US-6528601-B1 Storage stability, odorless TOKUYAMA CORPORATION (JP) 2003-03-04 US disclosed
US-20030036579-A1 Curable composition comprising a photochromic compound TOKUYAMA CORPORATION (JP) 2003-02-20 US disclosed
US-20030008958-A1 Curable composition and photochromic cured article TOKUYAMA CORPORATION (JP) 2003-01-09 US disclosed
EP-1184379-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2002-03-06 EP disclosed
EP-1130038-A1 CURABLE COMPOSITION TOKUYAMA CORPORATION (JP) 2001-09-05 EP disclosed
EP-1081145-A1 Polymerizable sulfur-containing (meth)acrylate, polymerizable composition and optical lens TOKUYAMA CORPORATION (JP) 2001-03-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014995-A1 Chromene compounds SMARCE1, SMARCB1, SMARCA2 ALDH1A1 2905/4885TSHR 3923/4885ACACB 2526/4885
US-20030096117-A1 Chromene compound SMARCE1, SMARCD2, SMARCB1 ALDH1A1 3101/4885TSHR 3797/4885ACACB 2730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.